G. Scoazec

Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors

V. de Lédinghen, J. Zucman‐Rossi, T. Asselah, 2022, JHEP reports : innovation in hepatology.

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor

J. Pawlotsky, F. Roudot-thoraval, A. Mallat, 2018, Alimentary pharmacology & therapeutics.

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

V. de Lédinghen, J. Zucman‐Rossi, T. Asselah, 2022, Journal of Cannabis Research.

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders

J. Pawlotsky, S. Chevaliez, S. Fourati, 2020, European journal of gastroenterology & hepatology.

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir‐containing regimen

J. Pawlotsky, F. Roudot-thoraval, A. Mallat, 2016, Hepatology.

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

V. de Lédinghen, T. Asselah, D. Thabut, 2021, BMC Infectious Diseases.

Retreatment of HCV DAA Failures: HCV Infection may be Incurable

J. Pawlotsky, A. Mallat, S. Chevaliez, 2016 .

Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C

J. Pawlotsky, F. Roudot-thoraval, A. Mallat, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

V. de Lédinghen, J. Zucman‐Rossi, M. Ronot, 2021, JHEP reports : innovation in hepatology.

Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis

V. Vilgrain, D. Valla, F. Durand, 2022, NEJM Evidence.

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)

V. de Lédinghen, J. Zucman‐Rossi, D. Thabut, 2023, Quality of Life Research.